Novartis, Monash University and Monash Health partner in bold vision for heart health
Posted: 14 May 2024 Today, Monash University, Monash Health and Novartis announced a unique Australian partnership in the fight against cardiovascular disease – Australia’s most significant health challenge responsible for 1 in 4 deaths and claiming an Australian life every 12 minutes.…
Cellular immunotherapy manufacturer secured – Cell Therapies
Posted: 14 May 2024 AdAlta Limited (ASX:1AD) (AdAlta) and Cell Therapies Pty Ltd (CTPL) are pleased to announce that they have executed a Master Services Agreement (MSA) establishing CTPL as AdAlta’s preferred manufacturing partner of cellular immunotherapies. This…
Optiscan Signs Know-How Agreement with Mayo Clinic
Posted: 14 May 2024 Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has entered into a collaboration through a know-how agreement (Agreement) with Mayo Clinic to develop a digital confocal laser endomicroscopic…
Landmark accelerator program launched at Burnet Institute
Posted: 13 May 2024 Burnet Institute is investing an initial $6.5 million in a landmark accelerator program – Burnext – designed to fast-track research into real-world outcomes to improve human health. Burnext will take research projects through an…
Crux Biolabs and KCAS Bio announce Global Spectral Flow Cytometry Alliance
Posted: 13 May 2024 KCAS Bio has selected Crux Biolabs (Melbourne, Australia) as its partner in providing harmonised spectral flow cytometry across the US, Europe, and Australia. The alliance enables KCAS Bio and Crux Biolabs to support the…
Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Posted: 8 May 2024 CUREator by Brandon BioCatalyst has announced the deployment of $7.21 million in funding to support eight biotech companies across their Clinical and Preclinical streams thanks to the Federal Government’s Medical Research Future Fund’s Early-Stage…
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Posted: 8 May 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its…
New industry-research partnership accelerates Medtech innovation in Melbourne
Posted: 7 May 2024 Australian medical device company Signature Orthopaedics is partnering with leading Medtech researchers at the University of Melbourne and RMIT University. The three-way strategic partnership connects research excellence in the fields of biomedical engineering, health,…
A $411 million commitment for researchers to bring their discoveries to life
Posted: 6 May 2024 The National Health and Medical Research Council (NHMRC) continues to invest in our nation’s health and medical research sector, with over $411 million awarded to 229 outstanding researchers to investigate Australia’s greatest health challenges.…
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Posted: 6 May 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces initial encouraging data from EFTISARC-NEO, a Phase II investigator-initiated…
DIMERIX RECEIVES APPROVAL FOR PAEDIATRIC INVESTIGATION PLAN FROM THE UK MHRA
Posted: 6 May 2024 Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Paediatric Investigation Plan (PIP) for…
One-two punch treatment delivers blood cancer knockout
Posted: 6 May 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study by WEHI…
